The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

The FDA says user challenges and need for additional procedures drove recommendations to stop using the system immediately.

Though arterial thrombotic risk was higher with hormonal contraception use, the absolute excess risks were low.

Intensifying oral diuretic therapy was linked to worse prognosis, but not everybody is sold on its use an endpoint.